Drugs & Targets FDA grants priority review for Imfinzi in gastric and GEJ cancer August 01, 2025Vol.51 No.30
Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER directorHis appointment came out of “proximity” to Makary and Bhattacharya July 25, 2025Vol.51 No.29By Claire Marie Porter
Cancer Policy Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad July 25, 2025Vol.51 No.29By Claire Marie Porter
Cancer Policy The effects of NIH, FDA cuts will be felt for decades, CBO report estimates July 25, 2025Vol.51 No.29By Paul Goldberg
Cancer Policy COI statement prohibits “unseemly advocacy,” “undue influence” by industry rep on ODAC July 25, 2025Vol.51 No.29By Paul Goldberg
Funding Opportunities FDA OCE issues RFA for cooperative agreements for evaluation of cardiotoxicity July 25, 2025Vol.51 No.29
Drugs & Targets FDA extends review period for Blenrep combinations after unfavorable ODAC vote, EU approval July 25, 2025Vol.51 No.29By Jacquelyn Cobb
Drugs & Targets FDA issues CRL for RP1+ nivolumab BLA for treatment of advanced melanoma July 25, 2025Vol.51 No.29
Drugs & Targets FDA grants Breakthrough Therapy designation to elironrasib for lung cancer July 25, 2025Vol.51 No.29
Regulatory News ODAC nixes GSK’s Blenrep myeloma regimens, citing ocular toxicity, dosing, applicability to U.S. population July 18, 2025Vol.51 No.28By Jacquelyn Cobb and Sara Willa Ernst
